Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
NEW YORK, Feb. 27, 2018 -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Details of the presentation are below:
Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Time: 12:30pm PT / 3:30pm ET
A live webcast of the presentation may be accessed at http://wsw.com/webcast/roth32/eyen/ or on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Lee Roth / Tram Bui
The Ruth Group
Phone: 646-536-7012/7035
E-mail: [email protected]/[email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]
